Announcement • Jul 23
Lonza Group Ag Provides Earnings Guidance for the Second Half and Full Year 2026 Lonza Group AG provided earnings guidance for the second half and full year 2026. For the second half, as the company did exceptionally strong performance in this business platform in H1 2026 and anticipate higher absolute sales in H2, the company envisage that CER sales growth will moderate in H2 as planned due to a combination of less favorable phasing and portfolio mix alongside a higher base in H2 2025. Similarly, margins will normalize in the second half of the year as expected.
For the full year, the company full year 2026 sales expected to be broadly flat versus full year 2025 at around CHF 0.6 billion. Reported Earnings • Jul 22
First half 2026 earnings released: EPS: CHF8.14 (vs CHF5.65 in 1H 2025) First half 2026 results: EPS: CHF8.14 (up from CHF5.65 in 1H 2025). Revenue: CHF3.37b (up 11% from 1H 2025). Net income: CHF568.0m (up 43% from 1H 2025). Profit margin: 17% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year. Announcement • Jun 25
Lonza Group Reportedly Explores Sale of Capsules and Health Ingredients Division Lonza Group Ltd. (SWX:LONN) is reportedly exploring the sale of its capsules and health ingredients division, valued at approximately €2,500 million, as part of a strategic portfolio review. The planned divestment is intended to refocus the Swiss contract development and manufacturing organization (CDMO) on its core biologics and drug substance services, according to reports from Russian news agency AK&M. The report, dated June 19, 2026, indicates that Lonza Group is collaborating with Bank of America and Centerview Partners to assess the potential sale of this division. Notable private equity firms, including Lone Star (Lone Star Americas Acquisitions, Inc.), Altaris (Altaris, LLC), and One Rock Capital Partners (One Rock Capital Partners, LLC), are among the potential bidders vying for the business, which would represent a significant carve-out from Lonza's existing portfolio. This move aligns with a broader trend observed among European life-science suppliers, who are increasingly concentrating on higher-margin contract development and manufacturing services. As companies like Catalent and Sartorius have shown, there is a growing focus on capital allocation discipline and portfolio streamlining. Lonza Group's reported divestment is consistent with this narrative, sharpening its exposure to biologics and complex therapies, while divesting from more commoditized activities. Announcement • Jun 09
LONZA GROUP LTD Announces Management Changes LONZA GROUP LTD announced the appointment of Hans Trees as Global Head of Communications, Senior Vice President and member of the Extended Executive Committee. Hans will join Lonza on 1 September 2026 and succeed David Carter, who has led Lonza's Communications function since 2019. Hans is a seasoned communications executive with broad experience across communications, strategy and business leadership in global organizations. Most recently, he served as Roche's Global Head of External Engagement. Over an 11-year career at Roche, he held a number of leadership roles in both the Pharmaceuticals Division and Group functions. Prior to joining Roche, he worked in management consulting at AON and investment banking at Rothschild. Hans holds degrees from the University of Cambridge, the London School of Economics and University of Durham. Board Change • Jun 01
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Director Steve Fry was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 05
Upcoming dividend of CHF5.00 per share Eligible shareholders must have bought the stock before 12 May 2026. Payment date: 15 May 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (0.9%). Announcement • Apr 24
Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug Products Simulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives. Announcement • Apr 16
Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026 Lonza Group AG proposed final cash dividend of CHF 2.50 per share (Gross dividend per equity), Net dividend per equity of CHF 1.625 per share. Date of GM: May 8, 2026, Ex date: May 12, 2026, Payment date: May 15, 2026, Record date: May 13, 2026. New Risk • Apr 03
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 45% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Declared Dividend • Apr 03
Dividend increased to CHF5.00 Dividend of CHF5.00 is 25% higher than last year. Ex-date: 12th May 2026 Payment date: 15th May 2026 Dividend yield will be 1.0%, which is higher than the industry average of 0.5%. Announcement • Apr 02
Lonza Group AG, Annual General Meeting, May 08, 2026 Lonza Group AG, Annual General Meeting, May 08, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Apr 02
Full year 2025 earnings released: EPS: CHF12.98 (vs CHF8.94 in FY 2024) Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Reported Earnings • Jan 30
Full year 2025 earnings released: EPS: CHF12.98 (vs CHF8.94 in FY 2024) Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Oct 24
Lonza Group Ag Affirms Earnings Guidance for 2025 Lonza Group AG affirmed earnings guidance for 2025. For the period, company expects CER sales growth of 20-21%. Announcement • Sep 13
Lonza Group AG Announces Executive Changes, Effective October 1, 2025 Lonza Group AG announced the appointment of Jason Berndt as Head of Group Operations, Executive Vice President, and member of the Executive Committee (EC), effective October 1, 2025. Jason brings over two decades of experience in global operations, having held leadership roles in operational excellence, manufacturing, supply chain management, technical services, and network transformations across leading pharmaceutical and consumer goods companies. He most recently served as Head of Global Technical Services and Senior Vice President at Bristol-Myers Squibb. Prior to this, he spent over eight years in leadership roles at Teva Pharmaceuticals, six years in manufacturing operations at Procter & Gamble, and two years as a consultant at McKinsey and Company. Jason began his career in the US Army, serving five years as a military officer. He holds a Bachelor of Science degree from the United States Military Academy at West Point and an MBA from the University of Michigan. Maria Soler Nunez, currently Head of Group Operations, has been appointed as Chief Quality Officer and Executive Vice President, remaining a member of the EC, effective October 1, 2025. Maria joined Lonza in 2022 and has successfully led Lonza’s engineering, procurement, supply chain management, operational excellence, and program management Group Functions. In her new role, she will be responsible for upholding and reinforcing the highest quality standards across Lonza’s global development and manufacturing network, as well as overseeing regulatory affairs and regulatory compliance. Maria has 28 years of experience in manufacturing and quality roles in the pharmaceutical industry, having worked in multiple countries including Spain, Switzerland, and the US. Before joining Lonza, she served as Chief Quality Officer at Novartis and worked with Eli Lilly and Company for 12 years. Commencing 1 October 2025 and continuing until his retirement in 2026, Oliver Schläfli, currently serving as Global Head of Quality, will transfer his responsibilities to Maria and provide counsel on different projects across the organization. Reported Earnings • Jul 24
First half 2025 earnings released: EPS: CHF6.08 (vs CHF4.61 in 1H 2024) First half 2025 results: EPS: CHF6.08 (up from CHF4.61 in 1H 2024). Revenue: CHF3.58b (up 17% from 1H 2024). Net income: CHF426.0m (up 30% from 1H 2024). Profit margin: 12% (up from 11% in 1H 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Upcoming Dividend • May 06
Upcoming dividend of CHF4.00 per share Eligible shareholders must have bought the stock before 13 May 2025. Payment date: 15 May 2025. Payout ratio is a comfortable 45% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of British dividend payers (5.9%). In line with average of industry peers (0.7%). Reported Earnings • Apr 06
Full year 2024 earnings released: EPS: CHF8.94 (vs CHF8.88 in FY 2023) Full year 2024 results: EPS: CHF8.94. Revenue: CHF6.57b (down 2.1% from FY 2023). Net income: CHF636.0m (down 2.8% from FY 2023). Profit margin: 9.7% (in line with FY 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Declared Dividend • Apr 05
Dividend of CHF4.00 announced Shareholders will receive a dividend of CHF4.00. Ex-date: 13th May 2025 Payment date: 15th May 2025 Dividend yield will be 0.8%, which is higher than the industry average of 0.5%. Announcement • Feb 20
Lonza Reportedly Is Said to Tap Bofa, Centerview for Sale of Capsules Unit Lonza Group AG (SWX:LONN) has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ingredients business (Capsugel, Inc.), according to people familiar with the matter, as part of the firm’s efforts to streamline its corporate structure. The capsules unit could be worth at least €2.5 billion ($2.6 billion) in a deal, said one of the people, who asked not to be identified as the information is private. Deliberations are ongoing and details of a transaction could still change, the people said. New Risk • Jan 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 31% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Jan 30
Full year 2024 earnings released: EPS: CHF8.93 (vs CHF8.88 in FY 2023) Full year 2024 results: EPS: CHF8.93. Revenue: CHF6.57b (down 2.1% from FY 2023). Net income: CHF636.0m (down 2.8% from FY 2023). Profit margin: 9.7% (in line with FY 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Announcement • Oct 30
Lonza Group AG to Report First Half, 2025 Results on Jul 23, 2025 Lonza Group AG announced that they will report first half, 2025 results on Jul 23, 2025 Announcement • Oct 24
Lonza Group AG Provides Earnings Guidance for Full Year 2024 Lonza Group AG provided earnings guidance for full year 2024. The company reported a third quarter performance in line to deliver on its Full-year Outlook, with sales accelerating in fourth quarter based on the timing of batch releases. In this context, the company confirms its Full-year Outlook 2024 at flat year-on year sales in CER and a CORE EBITDA margin of high 20s. Operations at the new highly potent API facility in Visp are expected to commence in fourth quarter of 2024, with a significant sales contribution expected in 2025. Furthermore, construction remains on track at the large-scale commercial aseptic drug product facility in Stein (CH). Announcement • Oct 02
Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Lonza Group AG (SWX:LONN) entered into an agreement to acquire Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG) for $1.2 billion on March 20, 2024. Under the agreement, approximately 750 Genentech employees at the Vacaville (US) facility will be offered employment by Lonza. The transaction is subject to customary closing conditions. Upon closing, the Vacaville (US) site will be integrated into Lonza’s Biologics division, joining a network of existing mammalian manufacturing sites in Visp (CH), Slough (UK), Singapore (SG), Portsmouth (US) and Porriño (ES). The transaction is expected to close in H2 2024. As the transaction is expected to be accretive to sales growth, Lonza has updated its Mid-Term Guidance 2024 – 2028. BofA Securities acted as financial advisors to Lonza.
Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG) on October 1, 2024. Reported Earnings • Jul 28
First half 2024 earnings released: EPS: CHF4.61 (vs CHF5.54 in 1H 2023) First half 2024 results: EPS: CHF4.61 (down from CHF5.54 in 1H 2023). Revenue: CHF3.06b (flat on 1H 2023). Net income: CHF329.0m (down 20% from 1H 2023). Profit margin: 11% (down from 13% in 1H 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Jul 26
Lonza Group AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Lonza Group AG announced that they will report fiscal year 2024 results on Jan 30, 2025 Buy Or Sell Opportunity • Jul 26
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 6.3% to CHF558. The fair value is estimated to be CHF451, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Buy Or Sell Opportunity • May 29
Now 22% undervalued Over the last 90 days, the stock has risen 4.3% to CHF483. The fair value is estimated to be CHF618, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Buy Or Sell Opportunity • May 15
Now 22% undervalued Over the last 90 days, the stock has risen 11% to CHF505. The fair value is estimated to be CHF644, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Announcement • May 12
Lonza Group AG Announces Board Changes Lonza Group AG announced that Albert M. Baehny, former Chairman of the Board of Directors, did not stand for re-election at the Annual General Meeting (AGM) of 8 May 2024. Jean-Marc Huët has been elected as new member and Chairman of the Board of Directors at this AGM. Announcement • May 11
Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024 Lonza Group AG at its AGM held on May 8, 2024 approved Final cash dividend of CHF 2.00 per share and Share premium dividend of CHF 2.00 per share. Ex date is May 13, 2024, payment date is May 15, 2024 and record date is May 14, 2024. Buy Or Sell Opportunity • Apr 19
Now 20% undervalued Over the last 90 days, the stock has risen 38% to CHF501. The fair value is estimated to be CHF630, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Reported Earnings • Apr 04
Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022) Full year 2023 results: EPS: CHF8.88 (down from CHF16.37 in FY 2022). Revenue: CHF6.72b (up 7.9% from FY 2022). Net income: CHF654.0m (down 46% from FY 2022). Profit margin: 9.7% (down from 20% in FY 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Declared Dividend • Apr 04
Dividend of CHF2.00 announced Shareholders will receive a dividend of CHF2.00. Ex-date: 13th May 2024 Payment date: 15th May 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.5%. New Risk • Apr 04
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.7% net profit margin). Announcement • Apr 02
Lonza Group AG Announces Chief Executive Officer Changes Lonza Group AG announced that Wolfgang Wienand has been appointed Chief Executive Officer (CEO), and will join the company during the summer of 2024. Wolfgang is currently CEO of the Swiss contract development and manufacturing organization (CDMO) Siegfried Holding AG, a role he has held since 2019. Prior to this, Wolfgang first served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Before joining Siegfried in 2010, Wolfgang held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries. Wolfgang will succeed Albert M. Baehny, who took on the additional responsibility of CEO on an ad interim basis in October 2023 while the search for a permanent CEO took place. Albert will remain at Lonza for a transition period during the summer, before retiring from the company. Reported Earnings • Jan 26
Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022) Full year 2023 results: EPS: CHF8.88 (down from CHF16.37 in FY 2022). Revenue: CHF6.72b (up 7.9% from FY 2022). Net income: CHF654.0m (down 46% from FY 2022). Profit margin: 9.7% (down from 20% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Jan 12
Lonza Group AG to Report Fiscal Year 2023 Results on Jan 26, 2024 Lonza Group AG announced that they will report fiscal year 2023 results on Jan 26, 2024 Announcement • Jan 07
Lonza Group AG, Annual General Meeting, May 08, 2024 Lonza Group AG, Annual General Meeting, May 08, 2024. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CHF345, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF513 per share. Announcement • Sep 21
Lonza Group AG Provides Sales Guidance for the Year 2023 Lonza Group AG provided sales guidance for the year 2023. The company is reconfirming its Outlook 2023. During the company’s Half-Year Results presentation in July 2023, the Outlook was set at mid-to-high single-digit CER sales growth. Announcement • Sep 18
Lonza Group AG Announces CEO Changes Lonza Group AG announced that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September 2023 by mutual agreement. The Board of Directors also announced that Albert M. Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is appointed. Reported Earnings • Jul 23
First half 2023 earnings released: EPS: CHF5.54 (vs CHF6.67 in 1H 2022) First half 2023 results: EPS: CHF5.54 (down from CHF6.67 in 1H 2022). Revenue: CHF3.08b (up 3.2% from 1H 2022). Net income: CHF410.0m (down 17% from 1H 2022). Profit margin: 13% (down from 17% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Jun 02
Lonza Group AG (SWX:LONN) acquired Synaffix BV. Lonza Group AG (SWX:LONN) acquired Synaffix BV for €160 million on June 1, 2023. The consideration comprises an initial financial consideration of €100 million in cash and up to €60 million in additional performance-based consideration. Synaffix will continue to operate under the Synaffix name and further expand its operations in Oss (NL). Bird & Bird LLP, Netherlands acted as legal advisor to Lonza Group. William Blair & Company, L.L.C. acted as financial advisor, Goodwin Procter LLP and NautaDutilh N.V. acted as legal advisor to Synaffix.
Lonza Group AG (SWX:LONN) completed the acquisition of Synaffix BV on June 1, 2023. Announcement • May 11
Lonza Group AG Reiterates Sales Guidance for the Years 2023 Lonza Group AG reiterated sales guidance for the years 2023. For the year 2023, the company reiterates high single digit CER sales growth. Upcoming Dividend • May 02
Upcoming dividend of CHF3.50 per share at 0.6% yield Eligible shareholders must have bought the stock before 09 May 2023. Payment date: 11 May 2023. Payout ratio is a comfortable 21% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of British dividend payers (5.8%). In line with average of industry peers (0.7%). Reported Earnings • Mar 29
Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021) Full year 2022 results: EPS: CHF16.37 (up from CHF9.08 in FY 2021). Revenue: CHF6.22b (up 15% from FY 2021). Net income: CHF1.22b (up 80% from FY 2021). Profit margin: 20% (up from 13% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Jan 27
Lonza Group AG to Report First Half, 2023 Results on Jul 21, 2023 Lonza Group AG announced that they will report first half, 2023 results on Jul 21, 2023 Reported Earnings • Jan 26
Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021) Full year 2022 results: EPS: CHF16.37 (up from CHF9.08 in FY 2021). Revenue: CHF6.22b (up 15% from FY 2021). Net income: CHF1.22b (up 80% from FY 2021). Profit margin: 20% (up from 13% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Jan 26
Lonza Group AG Provides Earnings Guidance for the Year 2023 Lonza Group AG provided earnings guidance for the year 2023. The company anticipates delivering high single-digit sales growth at constant currency with a margin of 30% to 31% in 2023. Announcement • Jan 25
Lonza Group AG (SWX:LONN) announces an Equity Buyback for CHF 2,000 million worth of its shares. Lonza Group AG (SWX:LONN) announces a share repurchase program. Under the program, the company will repurchase up to CHF 2,000 million worth of its shares. The purpose of the program is to initiate the return of excess capital to shareholders. The program is expected to be completed in H1 2025. Announcement • Jan 08
Lonza Group AG to Report Fiscal Year 2022 Results on Jan 25, 2023 Lonza Group AG announced that they will report fiscal year 2022 results on Jan 25, 2023 Reported Earnings • Jul 22
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CHF261.0m from profit in 1H 2021). Profit margin: (down from 10% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 12%, compared to a 25% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • May 02
Upcoming dividend of CHF3.00 per share Eligible shareholders must have bought the stock before 09 May 2022. Payment date: 11 May 2022. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of British dividend payers (4.6%). In line with average of industry peers (0.6%). Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Dorothee Deuring was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 27
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: CHF9.08 (down from CHF9.81 in FY 2020). Revenue: CHF5.41b (up 20% from FY 2020). Net income: CHF674.0m (down 7.7% from FY 2020). Profit margin: 13% (down from 16% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 9.3%, compared to a 11% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings. Board Change • Dec 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Dorothée Deuring was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 24
First half 2021 earnings released: EPS CHF3.51 (vs CHF5.94 in 1H 2020) The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: CHF2.54b (up 13% from 1H 2020). Net income: CHF261.0m (down 41% from 1H 2020). Profit margin: 10% (down from 20% in 1H 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. Upcoming Dividend • May 04
Upcoming dividend of CHF3.00 per share Eligible shareholders must have bought the stock before 10 May 2021. Payment date: 12 May 2021. Trailing yield: 0.5%. Lower than top quartile of British dividend payers (4.0%). In line with average of industry peers (0.5%). Is New 90 Day High Low • Feb 15
New 90-day high: CHF609 The company is up 4.0% from its price of CHF588 on 17 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF341 per share. Announcement • Dec 25
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal Arbor Biotechnologies and Lonza announced a license agreement to provide Lonza with access to Arbor's next-generation CRISPR-based gene editing technology. Lonza will have the ability to utilize Arbor's proprietary technology in its bioproduction products and services. Announcement • Dec 17
Aurinia Pharmaceuticals Inc. and Lonza Group Ltd Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity Aurinia Pharmaceuticals Inc. and Lonza Ltd. announced that they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand. The new agreement builds on the parties' successful multi-year relationship. The agreement, which is conditional upon U.S. regulatory approval of voclosporin, does not impact the launch supply for voclosporin as this is secured by existing inventory. The monoplant is estimated to be operational in 2023. Following U.S. regulatory approval of voclosporin, Aurinia will commence several capital expenditure payments. Upon completion of the monoplant, Aurinia will have the right to maintain unobstructed use of the monoplant by paying a quarterly fixed facility fee. The U.S. Food and Drug Administration (FDA) accepted the filing of Aurinia’s NDA for voclosporin in the treatment of lupus nephritis (LN), granted Priority Review, and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 22, 2021. Announcement • Dec 03
Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates Lonza announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates at its Visp site. As part of Lonza's Ibex Dedicate model, a technology-agnostic supply solution that helps reduce time to market and control investment risk, two bioconjugation suites totaling 1,500m2 of active manufacturing space will be built out within a pre-existing shell. The new suites will also benefit from established quality control labs, logistics and other central services, allowing for faster ramp-up times, assured delivery and high performance. Announcement • Nov 20
Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network Lonza announced a strategic partnership with Be The Match Biotherapies, LLC to integrate solutions in CGT. The goal of the collaboration is to improve efficiency across the CGT supply chain, inclusive of apheresis network management, healthy donor tissue supply, manufacturing and, where appropriate, supply chain management and logistics. The partnership establishes Be The Match BioTherapies and Lonza as preferred partners and is aimed at supporting the companies' shared goal of providing end-to-end solutions that streamline the development of cell and gene therapies across the CGT supply chain. Lonza and Be The Match BioTherapies will integrate each other's services in their respective offerings to provide a seamless offering to customers. This collaboration builds on current partnerships announced by Lonza and Be The Match BioTherapies to build a seamless, vein-to-vein network for customers and their patients. Partners of Lonza include Cryoport, a leading temperature-controlled supply chain company, and Vineti, a company developing the first commercial, configurable, cloud-based digital platform to orchestrate advanced therapy supply chains. Be The Match BioTherapies brings expertise in successfully delivering more than 100,000 cell therapies, expertise in logistics, managing apheresis networks, and the ability to provide high-quality cellular source material from the Be The Match Registry® which offers the world's largest, most ethnically diverse listing of more than 22 million potential blood and marrow donors, with Lonza's capabilities in cell and gene therapy manufacturing. Is New 90 Day High Low • Nov 05
New 90-day high: CHF624 The company is up 9.0% from its price of CHF571 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF265 per share. Announcement • Nov 04
Lonza Group Ltd Announces Management Changes Pierre-Alain Ruffieux joins Lonza Group in the role of Chief Executive Officer. Albert Baehny has taken the role of CEO ad interim since November 2019. He will now work with Pierre-Alain to ensure a smooth handover of leadership before returning to his role as Chairman of the Board of Directors. Pierre-Alain brings with him more than 20 years of experience in biopharmaceuticals, most recently as Head of Global Pharma Technical Operations at Roche, where he oversaw pharmaceutical commercial manufacturing and supply chain operations. Is New 90 Day High Low • Oct 17
New 90-day high: CHF597 The company is up 8.0% from its price of CHF555 on 17 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF264 per share. Announcement • Oct 02
Lonza Reportedly Starts Disposal of Specialty Ingredients Unit Lonza Group Ltd. (SWX:LONN) has initiated the divestment of its Specialty Ingredients business and a potential deal may fetch up to CHF 3.5 billion (USD 3.81 billion/EUR 3.24 billion), Reuters said on September 30, 2020 citing sources in the know. Potential buyers, including both sector players and private equity investors, will be approached in October, according to the report. Lonza announced in July a plan to sell the business following its carve-out. The divestment will allow the company to focus on developing as a manufacturing partner in the pharma and biotech industry. Lonza agreed in May to provide production services to support US Moderna Inc.'s coronavirus vaccine project. 
